Theranostic systems combining fluorescence imaging in the second near-infrared window (NIR-II, 1000–1700 nm) and photothermal therapy (PTT) under safe laser fluence have great potential in preclinical research and clinical practice, but the development of such systems with sufficient effective NIR-II brightness and excellent photothermal properties is still challenging. Here we report a theranostic system based on semiconducting polymer nanoparticles (L1057 NPs) for NIR-II fluorescence imaging and PTT under a 980 nm laser irradiation, with low (25 mW/cm2) and high (720 mW/cm2) laser fluence, respectively. Taking into consideration multiple parameters including the extinction coefficient, the quantum yield, and the portion of emission in the NIR-II region, L1057 NPs have much higher effective NIR-II brightness than most reported organic NIR-II fluorophores. The high brightness, together with good stability and excellent biocompatibility, allows for real-time visualization of the whole body and brain vessels and the detection of cerebral ischemic stroke and tumors with high clarity. The excellent photothermal properties and high maximal permissible exposure limit at 980 nm allow L1057 NPs for PTT of tumors under safe laser fluence. This study demonstrates that L1057 NPs behave as an excellent theranostic system for NIR-II imaging and PTT under safe laser fluence and have great potential for a wide range of biomedical applications.

Second near-infrared (NIR-II, 1000−1700 nm) fluorescence bioimaging has attracted tremendous scientific interest and already been used in many biomedical studies. However, reports on organic NIR-II fluorescent probes for in vivo photoinduced imaging and simultaneous therapy, as well as the longterm tracing of specific biological objects, are still very rare. Herein we designed a single-molecular and NIR-II-emissive theranostic system by encapsulating a kind of aggregation-induced emission luminogen (AIEgen, named BPN-BBTD) with amphiphilic polymer. The ultra-stable BPN-BBTD nanoparticles were employed for the NIR-II fluorescence imaging and photothermal therapy of bladder tumors in vivo. The 785 nm excitation triggered photothermal therapy could completely eradicate the subcutaneous tumor and inhibit the growth of orthotopic tumors. Furthermore, BPN-BBTD nanoparticles were capable of monitoring subcutaneous and orthotopic tumors for a long time (32 days). Single-molecular and NIR-II-emitted aggregation-induced emission nanoparticles hold potential for the diagnosis, precise treatment, and metastasis monitoring of tumors in the future.

BackgroundCircular RNA (circRNA) is a type of circular endogenous RNA produced by special selective splicing and participates in progression of diverse diseases. However, the role of circRNA in clear cell renal cell carcinoma (ccRCC) is still rarely reported.MethodsWe detected lower circ-AKT3 expression in ccRCC using the circular RNA microarray. Then, qPCR array was applied to verify the expression of circ-AKT3 in between 60 ccRCC tissues and adjacent normal tissues, as well as ccRCC cell lines and human normal kidney cell (HK-2). We investigated the function of circ-AKT3 in ccRCC in vitro and in vivo and detected underlying mechanisms by Western blotting, bioinformatic analysis, RNA pull-down assay and luciferase reporter assay.ResultsCirc-AKT3 was verified significantly downregulated in ccRCC. Knockdown of circ-AKT3 promoted ccRCC migration and invasion, while overexpression of circ-AKT3 suppressed ccRCC metastasis. Further, circ-AKT3/miR-296-3p/E-cadherin axis was shown responsible for circ-AKT3 inhibiting ccRCC metastasis.ConclusionCirc-AKT3 suppresses ccRCC metastasis by enforcing E-cadherin expression through competitively binding miR-296-3p. Circ-AKT3 may therefore serve as a novel therapeutic to better suppress ccRCC metastasis.